Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/29553
Type
ArticleCopyright
Restricted access
Embargo date
2028-08-30
Collections
- INI - Artigos de Periódicos [3498]
Metadata
Show full item record
EFFECTS OF EMTRICITABINE/TENOFOVIR ON BONE MINERAL DENSITY IN HIV-NEGATIVE PERSONS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Author
Mulligan, Kathleen
Glidden, David V
Anderson, Peter L
Liu, Albert
McMahan, Vanessa
Gonzales, Pedro
Ramirez-Cardich, Maria Esther
Namwongprom, Sirianong
Chodacki, Piotr
Mendonça, Laura Maria Carvalo
Wang, Furong
Lama, Javier R
Chariyalertsak, Suwat
Guanira, Juan Vicente
Buchbinder, Susan
Bekker, Linda-Gail
Schechter, Mauro
Veloso,Valdiléa G.
Grant, Robert M
Preexposure Prophylaxis Initiative Study Team
Glidden, David V
Anderson, Peter L
Liu, Albert
McMahan, Vanessa
Gonzales, Pedro
Ramirez-Cardich, Maria Esther
Namwongprom, Sirianong
Chodacki, Piotr
Mendonça, Laura Maria Carvalo
Wang, Furong
Lama, Javier R
Chariyalertsak, Suwat
Guanira, Juan Vicente
Buchbinder, Susan
Bekker, Linda-Gail
Schechter, Mauro
Veloso,Valdiléa G.
Grant, Robert M
Preexposure Prophylaxis Initiative Study Team
Affilliation
University of California. San Francisco, USA.
University of California. San Francisco, USA.
University of Colorado Denver. Aurora, USA.
University of California. San Francisco Bridge HIV. San Francisco Department of Public Health. California, USA.
Gladstone Institute of Virology and Immunology. San Francisco, California, USA.
Investigaciones Medicas en Salud. Peru.
Asociacion Civil Impacta Salud y Education. Lima, Peru.
Chiang Mai University. Thailand.
University of Cape Town. Desmond Tutu HIV Centre and Department of Medicine. South Africa.
Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.
University of California. San Francisco, USA.
Asociacion Civil Impacta Salud y Education. Lima, Peru.
Chiang Mai University. Thailand Research Institute for Health Sciences. Chiang Mai, Thailand.
Investigaciones Medicas en Salud. Peru.
University of California. San Francisco Bridge HIV. San Francisco Department of Public Health. California, USA.
University of Cape Town. Desmond Tutu HIV Centre and Department of Medicine. South Africa.
Universidade Federal do Rio de Janeiro. Hospital Escola São Francisco de Assis. Projeto Praça Onze. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of California./ Gladstone Institute of Virology and Immunology. San Francisco, California, USA.
University of California. San Francisco, USA.
University of Colorado Denver. Aurora, USA.
University of California. San Francisco Bridge HIV. San Francisco Department of Public Health. California, USA.
Gladstone Institute of Virology and Immunology. San Francisco, California, USA.
Investigaciones Medicas en Salud. Peru.
Asociacion Civil Impacta Salud y Education. Lima, Peru.
Chiang Mai University. Thailand.
University of Cape Town. Desmond Tutu HIV Centre and Department of Medicine. South Africa.
Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.
University of California. San Francisco, USA.
Asociacion Civil Impacta Salud y Education. Lima, Peru.
Chiang Mai University. Thailand Research Institute for Health Sciences. Chiang Mai, Thailand.
Investigaciones Medicas en Salud. Peru.
University of California. San Francisco Bridge HIV. San Francisco Department of Public Health. California, USA.
University of Cape Town. Desmond Tutu HIV Centre and Department of Medicine. South Africa.
Universidade Federal do Rio de Janeiro. Hospital Escola São Francisco de Assis. Projeto Praça Onze. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of California./ Gladstone Institute of Virology and Immunology. San Francisco, California, USA.
Abstract
Daily preexposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency virus (HIV) acquisition. Initiation of TDF decreases bone mineral density (BMD) in HIV-infected people. We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men and in transgender women.
Share